Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sodium valproate-induced hyperammonemia without clinical hepatic dysfunction.

B S Zaret, R R Beckner, A M Marini

    Neurology
    |February 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Corrigendum to: "Transcriptional and epigenetic analyses of the DMD locus reveal novel cis-acting DNA elements that govern muscle dystrophin expression". [Biochim. Biophys. Acta Gene Regul. Mech. 2017 Nov;1860(11):1138-1147.].

    Biochimica et biophysica acta. Gene regulatory mechanisms·2020
    Same author

    Correlation between individual inflammation genetic profile and platelet rich plasma efficacy in hair follicle regeneration: a pilot study reveals prognostic value of IL-1a polymorphism.

    European review for medical and pharmacological sciences·2017
    Same author

    Yeast nitrogen catabolite repression is sustained by signals distinct from glutamine and glutamate reservoirs.

    Molecular microbiology·2015
    Same author

    Geometrically constrained derivatives of indolylglyoxylamides as ligands binding the GABAA/BzR complex.

    Current topics in medicinal chemistry·2011
    Same author

    Effect of protein glutathionylation on neuronal cytoskeleton: a potential link to neurodegeneration.

    Neuroscience·2011
    Same author

    Recent advances in the development of dual topoisomerase I and II inhibitors as anticancer drugs.

    Current medicinal chemistry·2010
    Same journal

    Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

    Neurology·2026
    Same journal

    Association of Changes in Intrinsic Capacity With Cognitive Decline and Dementia: A Prospective Cohort Study.

    Neurology·2026
    Same journal

    Role of the Upper Motor Neuron in the Generation of Fasciculations in Early Disease Stages of Amyotrophic Lateral Sclerosis.

    Neurology·2026
    Same journal

    Factors Associated With Disability Improvement and Worsening Independent of Attacks in Patients With AQP4-IgG+ NMOSD and MOGAD: A Multicenter Cohort Study.

    Neurology·2026
    Same journal

    Cost-Effectiveness of Intracranial Aneurysm Screening: A Systematic Review.

    Neurology·2026
    Same journal

    Rare Eating Epilepsy: Co-Occurrence of Focal Cortical Dysplasia and Gray Matter Heterotopia.

    Neurology·2026
    See all related articles

    Valproic acid (VPA) can cause hyperammonemia and neurological issues in adults, even with normal liver function. Reducing VPA dosage is key to resolving these serious gastrointestinal and encephalopathy symptoms.

    Area of Science:

    • Neurology
    • Clinical Pharmacology
    • Toxicology

    Background:

    • Valproic acid (VPA) is a widely used antiepileptic drug.
    • Hyperammonemia is a known, albeit uncommon, side effect of VPA.
    • The relationship between VPA, protein intake, and hyperammonemia in adults requires further elucidation.

    Purpose of the Study:

    • To investigate the occurrence and characteristics of hyperammonemia in adult patients receiving VPA.
    • To explore the correlation between VPA dosage, serum VPA concentrations, and arterial ammonium levels.
    • To assess the impact of VPA-induced hyperammonemia on neurological and gastrointestinal symptoms.

    Main Methods:

    • Case series of three adult patients on unrestricted protein diets receiving VPA.
    • Monitoring of gastrointestinal symptoms, encephalopathy, and seizure control.

    Related Experiment Videos

  • Measurement of arterial ammonium levels, serum VPA concentrations, and liver function tests.
  • Evaluation of phenobarbital concentrations in relevant patients.

    • Main Results:

    • Three adult patients developed gastrointestinal symptoms and/or encephalopathy with hyperammonemia while on VPA.
    • Symptoms and hyperammonemia did not directly correlate with VPA dosage or serum VPA levels.
    • Neurologic and gastrointestinal symptom remission was linked to VPA concentration reduction.
    • One patient experienced recurrent hyperammonemia upon VPA rechallenge.

    Conclusions:

    • Valproic acid can induce significant hyperammonemia and associated neurological complications in adults, independent of liver function.
    • The clinical presentation and severity of hyperammonemia may not correlate with VPA dosage or serum levels.
    • Management strategies should include monitoring for hyperammonemia and considering VPA dose reduction for symptom resolution.